Impact of screening and exclusion of high anti-A titer donors on the risk of hemolytic anemia with intravenous immunoglobulin treatment: A hospital-based cohort study in the US.
作者信息
Martinez Carlos, Watson Douglas J, Shebl Amgad, Wallenhorst Christopher, Hubsch Alphonse, Simon Toby L
机构信息
Institute for Epidemiology, Statistics and Informatics GmbH, Frankfurt, 60388, Germany.
CSL Behring LLC, King of Prussia.
出版信息
Am J Hematol. 2018 Jan;93(1):E17-E20. doi: 10.1002/ajh.24931. Epub 2017 Oct 31.
Abstract
摘要
相似文献
1
Impact of screening and exclusion of high anti-A titer donors on the risk of hemolytic anemia with intravenous immunoglobulin treatment: A hospital-based cohort study in the US.
Am J Hematol. 2018 Jan;93(1):E17-E20. doi: 10.1002/ajh.24931. Epub 2017 Oct 31.
2
Fetal intravenous immunoglobulin therapy in rhesus hemolytic disease.
Gynecol Obstet Invest. 2007;63(3):176-80. doi: 10.1159/000097661. Epub 2006 Dec 1.
3
Potential approaches to prevent uncommon hemolytic side effects of AB0 antibodies in plasma derivatives.
Biologicals. 2005 Mar;33(1):41-8. doi: 10.1016/j.biologicals.2004.10.004. Epub 2005 Jan 27.
4
High-dose intravenous immunoglobulin therapy in neonatal immune haemolytic jaundice.
Acta Paediatr. 2000 Mar;89(3):371-2. doi: 10.1080/080352500750028618.
5
Anti-A/B isoagglutinin reduction in an intravenous immunoglobulin product and risk of hemolytic anemia: a hospital-based cohort study.
Transfusion. 2020 Jul;60(7):1381-1390. doi: 10.1111/trf.15859. Epub 2020 Jun 2.
6
Acquired hemolytic anemia associated with IgA anti-e.
Transfusion. 1972 May-Jun;12(3):157-61. doi: 10.1111/j.1537-2995.1972.tb00002.x.
7
Massive intravascular haemolysis after high dose intravenous immunoglobulin therapy.
Br J Haematol. 2013 Mar;160(5):570. doi: 10.1111/bjh.12182. Epub 2013 Jan 7.
8
Antibody testing strategies for deceased donor kidney transplantation after immunomodulatory therapy.
Transplantation. 2011 Jul 15;92(1):48-53. doi: 10.1097/TP.0b013e31821eab8a.
9
Response to intravenous immunoglobulin G in an infant with immunoglobulin A-associated autoimmune haemolytic anaemia.
Vox Sang. 2004 Feb;86(2):151-3. doi: 10.1111/j.0042-9007.2004.00392.x.
10
Hemolytic anemia as a result of piperacillin/tazobactam administration: a case report and discussion of pathophysiology.
Mil Med. 2013 Sep;178(9):e1045-7. doi: 10.7205/MILMED-D-12-00512.
引用本文的文献
1
Anti-A/B isoagglutinin reduction in an intravenous immunoglobulin product and risk of hemolytic anemia: a hospital-based cohort study.
Transfusion. 2020 Jul;60(7):1381-1390. doi: 10.1111/trf.15859. Epub 2020 Jun 2.
2
Isoagglutinin reduction in intravenous immunoglobulin (IgPro10, Privigen) by specific immunoaffinity chromatography reduces its reporting rates of hemolytic reactions: an analysis of spontaneous adverse event reports.
Transfusion. 2020 Jun;60(6):1278-1286. doi: 10.1111/trf.15846. Epub 2020 May 14.
3
Efficacy and safety of IVIG in CIDP: Combined data of the PRIMA and PATH studies.
J Peripher Nerv Syst. 2019 Mar;24(1):48-55. doi: 10.1111/jns.12302. Epub 2019 Feb 15.
4
Adverse Effects of Immunoglobulin Therapy.
Front Immunol. 2018 Jun 8;9:1299. doi: 10.3389/fimmu.2018.01299. eCollection 2018.
本文引用的文献
1
Reduction of Isoagglutinin in Intravenous Immunoglobulin (IVIG) Using Blood Group A- and B-Specific Immunoaffinity Chromatography: Industry-Scale Assessment.
BioDrugs. 2016 Oct;30(5):441-451. doi: 10.1007/s40259-016-0192-3.
2
Isoagglutinin Reduction in Human Immunoglobulin Products by Donor Screening.
Biol Ther. 2014 Dec;4(1-2):15-26. doi: 10.1007/s13554-014-0016-2. Epub 2014 May 20.
3
Hemolytic transfusion reactions after administration of intravenous immune (gamma) globulin: a case series analysis.
Transfusion. 2008 Aug;48(8):1598-601. doi: 10.1111/j.1537-2995.2008.01721.x. Epub 2008 May 2.
4
Hemolysis following intravenous immune globulin therapy.
Transfusion. 1986 Sep-Oct;26(5):410-2. doi: 10.1046/j.1537-2995.1986.26587020113.x.
Zotero 插件